Skip to main content

Branded

  • Diplomat to dispense Cuvitru

    FLINT, Mich. — Diplomat Pharmacy announced Monday that it had begun filling prescriptions for Shire’s Cuvitru, which launched last week following its September approval by the Food and Drug Administration. The drug treats primary humoral immunodeficiency in patients ages 2 years and older. 
     
    "We are excited to offer patients a therapy that expands their options for treating primary immunodeficiency," Diplomat president Paul Urick said. "Cuvitru is an important treatment for patients with unmet needs."

  • APhA celebrates 20 years of immunizing pharmacists

  • FDA approves Intarosa for post-menopausal pain during sex

    SILVER SPRING, Md. — The Food and Drug Administration on Thursday announced its approval of Quebec-based EndoCeutics’s Intarosa, a treatment for postmenopausal women experiencing pain during sex, a condition known as dyspareunia and a symptom of vulvar and vaginal atrophy. The condition is the result of a decline in estrogen levels that occurs during menopause. 
     

  • Gilead names Meyers EVP worldwide commercial operations

    FOSTER CITY, Calif. — Gilead Sciences on Thursday announced the promotion of James Meyers to the position of EVP worldwide commercial operations. In the new position, Meyers, who has been with Gilead since 1996, will be responsible for all North American, European and Japanese business operations and will become an officer of the company and a member of its senior leadership team. 
     

  • Newly minted Veru Healthcare names VP marketing

    MIAMI - Veru Healthcare on Wednesday named Shiao Zhu VP marketing for Veru Healthcare, which manages both the pharmaceuticals and medical devices as well as the consumer health divisions of The Female Health Company.

  • Shire launches Cuvitru

    LEXINGTON, Mass. — Shire on Wednesday announced the launch of its Cuvitru (immune globulin subcutaneous (human) 20% solution). The drug, which was approved in September, is indicated to treat adult and pediatric patients aged two years and over with primary immunodeficiency — a group of more than 300 genetic disorders that prevent the immune system from functioning properly. 
     

  • Report: Trump’s hints at FDA reform could bode well for pharma industry

    The Washington Post is reporting that President-elect Donald Trump’s transition website may be hinting to drug and medical device makers that under his administration, it might be easier to get their treatments to patients. The transition site promises that as president, Trump will “reform the Food and Drug Administration to put greater focus on the need of patients for new and innovative medical products.”
     

  • Study: Childhood exposure to flu protects against future strains

    PHOENIX - Your birth year predicts -- to a certain extent - how likely you are to get seriously ill or die in an outbreak of an animal-origin influenza virus, according to a study published last week that was co-led by researchers from the University of Arizona in Tucson and the University of California, Los Angeles.

X
This ad will auto-close in 10 seconds